Arrowstreet Capital Limited Partnership Has $473.05 Million Stake in Pfizer Inc. $PFE

Arrowstreet Capital Limited Partnership lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 0.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,565,451 shares of the biopharmaceutical company’s stock after selling 153,504 shares during the quarter. Arrowstreet Capital Limited Partnership owned about 0.33% of Pfizer worth $473,048,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Norges Bank acquired a new position in shares of Pfizer in the 2nd quarter valued at about $2,270,157,000. Vanguard Group Inc. grew its stake in Pfizer by 1.9% during the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock worth $12,928,730,000 after purchasing an additional 10,198,330 shares during the period. Franklin Resources Inc. increased its holdings in Pfizer by 47.8% in the third quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock worth $638,787,000 after purchasing an additional 8,108,887 shares in the last quarter. Neuberger Berman Group LLC lifted its stake in Pfizer by 203.8% in the third quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company’s stock valued at $229,346,000 after buying an additional 6,045,763 shares during the period. Finally, Assenagon Asset Management S.A. boosted its holdings in shares of Pfizer by 75.0% during the 3rd quarter. Assenagon Asset Management S.A. now owns 8,689,103 shares of the biopharmaceutical company’s stock worth $221,398,000 after buying an additional 3,722,531 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently commented on PFE shares. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. Citigroup started coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 target price on the stock. Wolfe Research set a $24.00 price target on shares of Pfizer and gave the stock an “underperform” rating in a report on Wednesday, December 17th. TD Cowen reaffirmed a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. Finally, BMO Capital Markets reissued an “outperform” rating and set a $30.00 price objective on shares of Pfizer in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $28.05.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approved Pfizer’s GLP‑1 weight management drug Xianweiying for long‑term weight management in adults — opens a large new market and adds a growth vector vs. GLP‑1 competitors. Pfizer’s Weight Management Drug Wins China Approval
• Positive Sentiment: Tilrekimig (trispecific antibody) reported encouraging Phase 2 eczema results — if confirmed in later‑stage trials this could meaningfully boost Pfizer’s immunology franchise and long‑term growth profile. How Tilrekimig’s Trispecific Eczema Data At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Pfizer advanced an early‑stage oncology candidate (PF‑07994525), adding to the company’s cancer pipeline and optionality. Early trials expand long‑term R&D upside. Pfizer Advances Early-Stage Cancer Candidate PF-07994525, Extending Its Oncology Pipeline
• Positive Sentiment: Completed Phase 2 toddler study for a next‑gen pneumococcal vaccine — progress here supports potential future vaccine launches and pediatric franchise strength. Pfizer Advances Next-Gen Pneumococcal Vaccine With Completed Phase 2 Toddler Study
• Neutral Sentiment: Market/sector roundups and commentary mention Pfizer among peers but provide no immediate catalyst. Useful for context but unlikely to move the stock alone. Health Care Roundup: Market Talk
• Neutral Sentiment: Executive commentary on navigating regulatory uncertainty highlights Pfizer’s regulatory expertise — background support but not an earnings driver. Be nimble, be ready: how to tackle regulatory uncertainty in clinical trials
• Negative Sentiment: Coverage notes Pfizer has dipped more than the broader market, reflecting short‑term underperformance and investor caution. Pfizer (PFE) Sees a More Significant Dip Than Broader Market: Some Facts to Know
• Negative Sentiment: Analyses questioning Pfizer’s valuation and post‑pandemic growth (patent cliffs, pipeline risks) continue to pressure sentiment — these narratives can cap multiple expansion until clearer revenue drivers emerge. Pfizer: Cheap For A Reason
• Negative Sentiment: Valuation/longer‑term value debates persist in recent pieces weighing pandemic sales declines and patent concerns against future pipeline gains. Does Pfizer (PFE) Offer Value After Post Pandemic Pipeline And Patent Concerns

Pfizer Stock Performance

Shares of PFE stock opened at $26.85 on Friday. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The firm has a fifty day simple moving average of $26.47 and a two-hundred day simple moving average of $25.51. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.94. The firm has a market capitalization of $152.65 billion, a PE ratio of 19.74 and a beta of 0.47.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business’s revenue was down 1.2% on a year-over-year basis. During the same period last year, the company earned $0.63 earnings per share. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.